Connect with us

India Hot Topics

Moderna Is Preparing For The Last Stage Trial Of The Corona Vaccine

Published

4 years ago

on

Moderna Is Preparing For The Last Stage Trial Of The Corona Vaccine

Relief news is coming to the people amidst the outbreak of the Corona epidemic. American drug maker Moderna is preparing for the last stage trial of the Coronavirus vaccine. According to the company, this trial can be started on July 27.

Moderna said that it would conduct trials of the vaccine at 87 locations in the US. 30 thousand people will be included in the test. People involved in the trial will be given a dose of 100 micrograms of the potential vaccine on the first day, followed by a second dose 29 days later. It is believed that after the third phase of the trial is successful, the company can make a big announcement.

American company Moderna’s Coronavirus vaccine was a complete success in its first trial. The study, published in the New England Journal of Medicine, says that the first test of this vaccine on 45 healthy people has had very good results.

Advertisement

This vaccine developed antibodies to rust from the corona within each individual. Another good thing about Moderna’s vaccine is that it did not have such a significant side effect, because of which the trial of vaccine should be stopped.

If antibodies are produced in initial testing, it is considered a major success, but this does not mean that this vaccine will be effective in eradicating the corona virus. This first test included 45 such people who were healthy and their age was between 18 and 55 years.

The trial of this potential vaccine will be done in 30 other states of the country besides the capital, Washington DC. More than half of the locations selected for vaccine trials are located in Texas, California, Florida, Georgia, Arizona, and North and South Carolina, the most affected by the corona virus.

The US government has also funded Moderna half a million dollars to develop the vaccine. The company claimed to be successful in taking the first two-phase trials of this vaccine. However, the data related to this has not been shared by the company.

Advertisement

According to reports, the shares of Moderna Company have increased more than three times since February. Listed on the US stock market Nasdaq, the company’s stock is valued at $ 74.57 on Tuesday. It is being told that after the successful testing of the Corona Virus Vaccine, this growth is seen in the shares of American pharmaceutical companies.

Let us know that at present there are more than 120 participants working on the coronavirus vaccine. However, 13 of these vaccines have reached the clinical trial phase. The maximum of these is in China’s vaccine human trial. Let us know that 5 in China, 2 in the UK, 3 in the US, Russia in Australia, and Germany 1-1 vaccine are in clinical trial phase.

Countries producing Corona vaccines and their companies are turning to India for its production. According to ICMR Director-General Dr. Balram Bhargava, Corona, India, which supplies 60 percent of the total vaccine worldwide, has a central role in the vaccine supply chain.

Along with this, giving information about the commencement of human trials of two indigenous vaccines, he said that their path will not be allowed to be delayed for even a day at the administrative level. Indicating vaccines as the last option in preventing corona infection, Dr. Balaram Bhargava said that all the countries of the world are fast-tracking the process of vaccine preparation and are getting success in it. He said that Russia has even completed the vaccine trial. Similarly, China, America, Britain, and other countries are busy preparing vaccines as soon as possible.

Advertisement

In India, human trials of India Biotech and Zydus Cadila vaccine have started. Dr. Balram Bhargava said that it is our moral responsibility to fast-track the indigenous vaccine and make it available to the common people at the earliest. He assured that the preparation of the indigenous vaccine will not be allowed to be delayed by even a day due to administrative reasons. In his July 2 letter, Dr. Bhargava, who talked about making the indigenous vaccine available to the general public by August 15, has not given any time limit for this. But he assured that the corona vaccine produced in the world will be available to people in India as well.

News Source: Reuters.Com

Also Read:What Makes Centre-State Relations Different In National Capital?

Advertisement
Related Topics:
Continue Reading

Tollywood

HT Rewind 2024: Teja Sajja says HanuMan kicking off the year in style is the moment he’d been ‘waiting for’ | Exclusive

Published

1 day ago

on

December 21, 2024

By

HT Rewind 2024: Teja Sajja says HanuMan kicking off the year in style is the moment he’d been ‘waiting for’ | Exclusive

In conversation with Hindustan Times, Teja Sajja decodes the success of HanuMan and other Telugu films, talks about his upcoming projects, and more.
When Prasanth Varma’s superhero film HanuMan, starring Teja Sajja, was announced to be released alongside big films like Mahesh Babu’s Guntur Kaaram, Venkatesh’s Saindhav and Nagarjuna’s Naa Saami Ranga in January this year, no one expected the underdog to emerge on top. And yet, the film, made on a budget of under ₹50 crore, managed to collect over ₹300 crore at the box office worldwide in 25 days, becoming one of the highest-grossing Indian films for the year. (Also Read: Ranveer Singh met HanuMan actor Teja Sajja, complimented him even after his Prasanth Varma film Rakshas got shelved)

Ask Teja about the moment he realised his film had not just fought against the tide but also risen to the top; he tells Hindustan Times in an exclusive conversation, “Since I returned to acting (as a lead actor after being a child artiste since 1998), this is the moment I’ve been waiting for. When everything from the HanuMan teaser to the songs was grabbing attention, we knew we had hit a gold mine. But I don’t think we imagined it would cross the ₹300 crore threshold. We were so satisfied with the opening numbers; everything else was a bonus.”

‘Success has given me fear of disappointing people’

Teja acted in Zombie Reddy, Ishq and Adbhutham before HanuMan, but they are what you would call ‘critical successes’, adding to his repertoire as an actor who can perform. But things have changed for him now, says Teja, who is being picky about the roles he says yes to. “Success either makes you overconfident or gives you the fear of disappointing people; I have the latter,” he explains.

Advertisement

Teja admits he wants to chart out his career in Hrithik Roshan’s footsteps, but not in the way you think. “I have such a fondness for Hrithik due to Koi Mil Gaya and Krrish. No matter how well he performed after that, these left a lasting impression on me; I’m sure 90s kids will agree,” he says, adding, “Similarly, I’ve realised that I have an audience in children now. I want to be conscious of that when I pick roles. I want to make films families can enjoy together.”

But despite people in places like Mumbai or Delhi recognising him, Teja says he’s clear that he wants to cater to the Telugu audience first. “I am conscious that I am making films for my playground – the Telugu states. This is the sensibility I have grown up with, and I don’t know if I can cater to everyone else. Will I promote my films in other languages? Sure. But I also can’t be part of films that aren’t authentic to what I know or understand,” he explains.

‘Rootedness has put us on the world map’

And authenticity seems to be the need of the hour. Be it Baahubali and RRR or the recently released Pushpa 2: The Rule, Kalki 2898 AD and Devara: Part 1, certain kind of stories seem to be finding success. “Rootedness and going local is proving to be such a boon for us, be it in Devara or Pushpa or HanuMan. Kalki 2898 AD was our version of a Hollywood film (the sci-fi concept) with actors from across languages in predominant roles; it put us on the world map,” reflects Teja.

However, the actor admits Tollywood went through a phase of Bollywood-inspired rom-coms and family dramas that worked in their favour for a while. “That wasn’t easy to replicate either, but it’s just that these local stories are what the audience seems most interested in now. It can’t just be chalked up to religion, too. It’s about the morals these films are hinged on, the fighting for righteousness, and how an underdog can find their strength. Introducing Mahabharata or Ramayana to a new audience in a cool way is just a perk,” he says.

Advertisement

And it’s this rootedness that Teja says his next films, Mirai and Jai Hanuman (the sequel to HanuMan), will also have ample of. “Mirai is also a superhero film that caters to kids, but it’s not an origin story like HanuMan. It has a pan-Asian and Buddhist touch because the story is based on King Ashoka’s ideologies. I hope that I will get to deliver something new to the audience again. I will only feel like I’ve arrived if Mirai is equally, if not more, successful,” says Teja.

Rishab Shetty will headline Jai Hanuman, but Teja also looks forward to shooting that. “I can’t wait to be on that set; it’ll be exciting. Now that we know India is ready to watch our films, I want to step it up. I want to shift gears and shoot for at least two films in 2025,” he says. As for what he will do next, Teja says he wants to up the ante. “When I got a SIIMA award for Zombie Reddy as a debutant, I remember telling Prasanth this would be the last award I get. But now that I won a Radio City Cine Award for Best Actor, I hope more awards will follow,” he signs off cheekily.

Group Media Publications
Entertainment News Platforms – anyflix.in      
Construction Infrastructure and Mining News Platform – https://cimreviews.com/
General News Platform – https://ihtlive.com/

Advertisement
Continue Reading
Anyskill-ads

Facebook

Trending